Intec Pharma Ltd. Partnered With LTS Lohmann Therapie-Systeme AG ("LTS") For Levodopa Market

 

Levodopa Market

Advancement in the diagnosis of Parkinson's disease (PD) progression is propelling the growth of the levodopa market. For instance, researchers continue developing new treatments for Parkinson's disease, treatments that give real hope for people suffering from the disease. Some treatments currently being studied involve fetal cell transplantation, the use of stem cells, and gene therapy. Moreover, the development of novel formulations and drug delivery methods for levodopa is also contributing to the growth of the levodopa market.

Levodopa is known by many names, including chelation therapy, L-carnitine, and nutritive adjuvant. It is a naturally occurring substance found in most tissues of the body, including the brain, heart, liver, kidney, pancreas, lungs, stomach, small intestine, and skeletal muscle tissue. This substance is often taken to treat various diseases, including Parkinson's disease and depression. As dopamine is responsible for feelings such as pleasure and excitement and is one of the neurotransmitters affected by disorders such as Parkinson's, using levodopa can help reduce some of these symptoms. Additionally, this substance has been shown to have beneficial effects on mood disorders, especially bipolar disorder. Levodopa can be taken in pill form

1.     In August 2019, The U.S. Food and Drug The administration approved Nourianz (istradefylline) tablets as an add-on treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) experiencing "off" episodes

2.     In February 2021, Adamas Pharmaceuticals, Inc. a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases announced it has received marketing authorization from the U.S. Food and Drug Administration (FDA) for a supplemental New Drug Application for GOCOVRI® (amantadine) extended-release capsules, gaining a second indication for the product.

3.     In March 2018, Intec Pharma Ltd. announces that it has partnered with LTS Lohmann Therapie-Systeme AG ("LTS") for the manufacture of the Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD) as a treatment for the severe symptoms in advanced Parkinson's disease patients.

North America is expected to dominate the global levodopa market and this is attributed to the high prevalence rate of Parkinson's disease in the region. According to the Parkinson's Foundation, nearly one million will be living with Parkinson's disease (PD) in the U.S. by 2020. Approximately 60,000 Americans are diagnosed with PD each year. More than 10 million people worldwide are living with PD. Men are 1.5 times more likely to have Parkinson's disease than women.

Comments

Popular posts from this blog

The Emergence of COVID-19 to Augment Growth of the Outsourced Drug Discovery Market

Otoscope Market Is Gaining Major Traction with Industry Leader Otonexus Medical Technologies Introducing Ultrasound Sensor, Which Aids Middle-Ear Infection Diagnosis

Increasing Demand for Healthcare Education to Augment the Healthcare Education Solution Market Growth